Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Cumulative Phase 2 clinical trials (trials): 46.00 trials in Q2 2026, up 7.0% from a year earlier. That is the highest of the 34 quarters on record here.
Latest, Q2 2026
46.00
Period ended Jun 30, 2026
Change on a year earlier
+7.0%
43.00 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
1
ClinicalTrials.gov API v2 (ModernaTX, Inc.)
Where the Q2 2026 figure comes from
Source: ClinicalTrials.gov API v2 (ModernaTX, Inc.) ↗
Reported in ClinicalTrials.gov API v2 (ModernaTX, Inc.).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Moderna Cumulative Phase 2 clinical trials (trials), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/ctgov-cum-phase2
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.